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Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in
classical Hodgkin and anaplastic large cell lymphoma
KD Wurster1,2, F Hummel1,2, J Richter3, M Giefing3,4, S Hartmann5, M-L Hansmann5, S Kreher2, K Köchert1,2, D Krappmann6, W Klapper7,
M Hummel8, S-S Wenzel2, G Lenz9, M Janz1,2, B Dörken1,2,10, R Siebert3,11 and S Mathas1,2,10
Apart from its unique histopathological appearance with rare tumor cells embedded in an inflammatory background of bystander
cells, classical Hodgkin lymphoma (cHL) is characterized by an unusual activation of a broad range of signaling pathways involved
in cellular activation. This includes constitutive high-level activity of nuclear factor-κB (NF-κB), Janus kinase/signal transducer and
activator of transcription (JAK/STAT), activator protein-1 (AP-1) and interferon regulatory factor (IRF) transcription factors (TFs) that
are physiologically only transiently activated. Here, we demonstrate that inactivation of the putative ubiquitin E3-ligase PDLIM2
contributes to this TF activation. PDLIM2 expression is lost at the mRNA and protein levels in the majority of cHL cell lines and
Hodgkin and Reed–Sternberg (HRS) cells of nearly all cHL primary samples. This loss is associated with PDLIM2 genomic alterations,
promoter methylation and altered splicing. Reconstitution of PDLIM2 in HRS cell lines inhibits proliferation, blocks NF-κB
transcriptional activity and contributes to cHL-specific gene expression. In non-Hodgkin B-cell lines, small interfering RNA-mediated
PDLIM2 knockdown results in superactivation of TFs NF-κB and AP-1 following phorbol 12-myristate 13-acetate (PMA) stimulation.
Furthermore, expression of PDLIM2 is lost in anaplastic large cell lymphoma (ALCL) that shares key biological aspects with cHL. We
conclude that inactivation of PDLIM2 is a recurrent finding in cHL and ALCL, promotes activation of inflammatory signaling
pathways and thereby contributes to their pathogenesis.
Leukemia (2017) 31, 602–613; doi:10.1038/leu.2016.238
INTRODUCTION
Classical Hodgkin lymphoma (cHL) is characterized by a unique
histopathological appearance in the affected lymph nodes
demonstrating only a minority of tumor cells, the so-called
Hodgkin and Reed–Sternberg (HRS) cells, that are embedded in an
abundant inflammatory microenvironment.1 It is assumed that
HRS cells attract these inflammatory bystander cells by high-level
production of cytokines and chemokines, and that the interaction
between HRS cells and their surrounding cells supports their
growth, survival and immune escape.1–3 The abundant production
of inflammatory mediators by HRS cells reflects their highly
activated phenotype. In line with such a phenotype, HRS cells
show constitutive activation of a plethora of transcription factors
(TFs) that are physiologically only transiently activated, and that
are implicated in cellular activation and immediate-early gene
induction. Among these TFs, nuclear factor-κB (NF-κB), signal
transducer and activator of transcription (STAT) 3, 5 and 6,
activator protein-1 (AP-1) and interferon regulatory factor-5 (IRF5)
play key roles in HL pathogenesis.4–8
The mechanisms leading to activation of these TFs in HRS cells
are complex and affect various layers of control of respective
pathway components.1 These include deleterious mutations of
negative regulators of receptor-proximal activation modules,9
of negative regulators of more downstream located signaling
components (for example, inhibitor of NF-κB (IκB)α mutations in
the NF-κB pathway),10,11 genomic alterations of respective TFs12,13
and the constitutive activation of upstream kinases.14 The strength
and plethora of pathway activation in HRS cells is exceptional
among lymphoid malignancies. Interestingly, despite their com-
plex transcriptional alterations including long-terminal repeat
activation,15,16 HRS cells demonstrate a surprisingly constant
phenotype. Our recent data on the pivotal role of IRF5 together
with NF-κB regarding the orchestration of the HL-specific gene
expression program7 suggest that only a limited number of
pathogenic events coordinate the cHL phenotype.
Given the number of high-level activated TFs in HRS cells
involved in immediate-early gene regulation, we postulated that
alterations of the ubiquitin system contribute to their simulta-
neous activation. Based on a literature search in combination with
gene expression data of HRS and non-Hodgkin (NH) B cell-derived
cell lines,17 we focused on PDLIM2 (also known as mystique or
SLIM).18–20 PDLIM2 has been shown to act as ubiquitin E3-ligase
inducing inactivation and degradation of TFs.19,21 In addition,
ubiquitin-independent mechanisms of PDLIM2 have been
described.19 By these mechanisms, PDLIM2 controls the activity
of TFs, such as NF-κB-p65, STAT1 and STAT3,19,21–23 that are highly
activated in HRS cells. Furthermore, alterations of PDLIM2 gene
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expression have been observed in malignancies,23–25 and the
PDLIM2 gene locus in 8p21.3 is in the minimal commonly deleted
region in 8p21.3 in several B-cell non-Hodgkin lymphomas.26,27
Here, we describe an inactivation of the putative ubiquitin
E3-ligase PDLIM2 as unifying defect of HRS cells. PDLIM2 loss of
expression is associated with various mechanisms, including
genomic alterations and promoter DNA methylation. Functionally,
loss of PDLIM2 promotes growth of HRS cells, facilitates the
activation of inflammatory TFs and results in deregulation of
differentially expressed cHL-associated genes, suggesting a
pathogenic role in cHL. Furthermore, we demonstrate loss of
PDLIM2 expression in anaplastic large cell lymphoma (ALCL) that
shares key biological aspects with cHL.
MATERIALS AND METHODS
Cell lines and culture conditions
HRS (L428, L1236, KM-H2, L591 (EBV+), U-HO1, SUP-HD1, HDLM-2, L540,
L540Cy), pro-B lymphoblastic leukemia (Reh), Burkitt lymphoma (Namalwa,
BL-60, BJAB), diffuse large B-cell lymphoma (SU-DHL-4), ALCL (K299, SU-
DHL-1, DEL, JB6, all anaplastic lymphoma kinase (ALK) positive; Mac-1, Mac-
2A, FE-PD, DL40, all ALK negative), T-cell leukemia-derived (Jurkat, KE-37,
Molt-14, H9) and HEK293 cells were cultured as previously described.28
Cells were electroporated in OPTI-MEM I using Gene-Pulser Xcell (Bio-Rad,
Munich, Germany) with 950 μF and 0.18 kV (L540Cy, HEK293) or 500 μF
and 0.3 kV (Reh, L591). Transfection efficiency was determined by pEGFP-
N3 (Clontech Laboratories, Mountain View, CA, USA) co-transfection. L591
and L540Cy cells were transfected with 40 μg of a pcDNA3-PDLIM2
transcript variant 2 (tv 2) construct along with 10 μg pEGFP-N3. GFP+ cells
were enriched by fluorescence-activated cell sorting. Reh cells were
transfected with two pSUPER plasmid29-based siPDLIM2 expression
plasmids (each 20 μg) or 40 μg of scrambled small interfering RNA (siRNA)
controls along with 10 μg pEGFP-N3 and enriched as previously
described.28 For reporter assays, L591, L540Cy or Reh cells were transfected
with 1 μg of 6xκBLuc or 15 μg 5xTRE reporter constructs, together with 50,
25 or 200 ng pRL-TKLuc as internal control. Where indicated, cells were
additionally transfected with 40 μg pcDNA3-IκBαΔN or pcDNA3-PDLIM2
constructs or controls. The ratio of the pRL-TKLuc and 6xκBLuc or 15 μg
5xTRE luciferase activities was determined (Dual luciferase kit; Promega,
Mannheim, Germany). Where indicated, cells were stimulated with
200 ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich,
Taufkirchen, Germany) or treated with 25 μg/ml cycloheximide
(Sigma-Aldrich).
DNA constructs
pcDNA3-IκBαΔN and luciferase constructs pGL3-6xκBLuc and pGL3-5xTRE-
TATA (kindly provided by Peter Angel, Heidelberg, Germany) have been
previously described.30,31 PDLIM2 plasmids encoding tv 1 (NM_176871.2;
1100 bp), variant 2 (NM_021630.4; 1058 bp) or PDLIM2_ΔLIM were
generated by cloning corresponding sequences through 5′ BamHI and 3′
XhoI (tv 1; ΔLIM) or EcoRI (tv 2; varL1236) into pcDNA3.1(+) (Invitrogen,
Karlsruhe, Germany). Primers used for amplification of PDLIM2 variants
were PDLIM2 BamHI s 5′-ACACGGATCCTCCACCATGGCGTTGACGGTGGA
TGTG-3′ and PDLIM2 XhoI as 5′-ACACGAATTCTCACCAGCTTGGCTGGATG
GG-3′ (tv 1) or PDLIM2 EcoRI as 5′-ACACGAATCCTCAGGCCCGAGAGCTG
AG-3′ (tv 2). PDLIM2_ΔLIM was amplified according to Tanaka et al.22
using primers PDLIM2 BamHI s and PDLIM2_ΔLIM XhoI as 5′-GC
CTCGAGTCAGGTGGCCAGGGCCCTG-3′. The truncated PDLIM2 variant
from L1236 cells was amplified using primers PDLIM2_varL1236 BamHI s
5′-GCGGATCCGCGTTGACGGTGGATGTGGCC-3′ and PDLIM2 EcoRI as. The, in
comparison with the wt PDLIM2 amplificate, smaller product was excised after
gel electrophoresis and cloned into pcDNA3 with N-terminal FLAG. Sequences
for the siPDLIM2 constructs were selected from the Dharmacon PDLIM2
ON-TARGETplus SMARTpool (J-010731; Dharmacon, Lafayette, CO, USA). Target
sequences 5′-GGACAGCTCCTTGGAAGTG-3′ or 5′-ACATAATCGTGGCCATCAA-3′
were cloned through BglII and HindIII restriction sites into pSUPER.29
The scrambled siRNA construct has been previously described.32 All DNA
constructs were verified by sequencing.
RNA preparation and reverse transcriptase-PCR analyses
Total RNA preparation, complementary DNA synthesis and semiquantita-
tive PCR and real-time quantitative PCR analyses were performed as
previously described.17,28 Primers are listed in Supplementary Table 1.
All PCR products were verified by sequencing.
Analysis of apoptosis and proliferation
The percentage of viable and apoptotic cells was determined by Annexin
V-fluorescein isothiocyanate/propidium iodide double staining (Bender
MedSystems, Vienna, Austria) and flow cytometry as previously described.7
Proliferation of cells was determined by measurement of [3H]-thymidine
incorporation using standard protocols.
Western blot analyses
Whole-cell and nuclear extract preparation and western blotting were
performed as described5 with 30 μg whole-cell or 20 μg nuclear extracts.
Primary antibodies were: PDLIM2 (sc-79988), IκBα (sc-371; both from Santa
Cruz, Heidelberg, Germany), PDLIM2 (ab68220; Abcam, Cambridge, UK)
and β-actin (A5316, Sigma-Aldrich).
Immunohistochemistry
Immunohistochemical stainings of 20 primary cHL, 10 follicular lymphoma,
15 diffuse large B-cell lymphoma and 10 Burkitt lymphoma cases
were performed as previously described.33 Primary antibodies (PDLIM2,
PA5-31484, Thermo Scientific, Darmstadt, Germany; PDLIM2, ab68220,
Abcam; IκBα, sc-371, Santa Cruz) were applied in a dilution of 1:100
(PDLIM2 antibodies) or 1:500 (IκBα) overnight.
Interphase cytogenetics
Fluorescence in situ hybridization and FICTION (fluorescence immunophe-
notyping and interphase cytogenetic as a tool for investigation of
neoplasia) techniques were used to analyze copy number changes of
the PDLIM2 gene in cHL cell lines and primary samples on cryosections
from the Department of Pathology, Hematopathology Section and Lymph
Node Registry, University Hospital Schleswig-Holstein, Kiel, Germany.
The anonymized use of these patient samples followed the regulations
approved by the institutional review board of the Medical Faculty of the
Christian-Albrechts-University Kiel (decision D447/10). For FICTION, the
procedure included pretreatment with anti-CD30 antibody (BerH2
generated in-house34) and detection with Alexa-594-conjugated antibody
(Molecular Probes, Leiden, The Netherlands). Two hybridization probes
were prepared as previously described.35 They contained DNA from
the 157 423 kb large BAC RP11-382J24 (NCBI AC087854.11;
chr8:22 225 035–22 382 458 genomic position based on the BAC and
sequences mapped to the hg19 assembly) containing the SLC39A14 and
PPP3CC genes (Invitrogen, GmbH, Darmstadt, Germany) labeled in
SpectrumGreen (Abbott/Vysis, Downers Grove, IL, USA) located in the
minimally deleted region in B-cell lymphomas 8p21.3(ref. 27) ∼ 55 kbp
telomeric of the PDLIM2 gene. This probe was combined either with the
centromeric CEP10 SpectrumAqua probe (assay 1) or the centromeric CEP8
SpectrumOrange probe (assay 2) (both Abbott/Vysis) that served as
internal controls. Both assays were used independently to the analyzed
samples. For evaluation, a Zeiss fluorescence microscope (Göttingen,
Germany) was used. For each case, at least 5 large CD30+ cells were
evaluated independently by two observers. We estimated the ploidy levels
of the analyzed cases by taking median signal numbers for the centromeric
probes CEP6,(ref. 9) CEP10 (this study), CEP16(ref. 15) and CEP17.36 For
detection of PDLIM2 deletions, the signal number of the RP11-382J24
probe (PDLIM2) was compared with the ploidy of the respective case
separately for both used assays (Supplementary Table 2). Lower number
of RP11-382J24 probe signals than the ploidy in at least 30% of the nuclei
of the case observed in both assays was indicative for a deletion.
Bisulfite pyrosequencing
Bisulfite pyrosequencing of two PDLIM2 promoter regions called ‘promoter
1’ (P1; promoter region of NM_021630) and ‘promoter 2’ (P2; promoter
region of NM_198042, NM_176871) and a previously analyzed region
(Qu et al.24,25 called ‘pub. reg.’) was performed according to standard
protocols with few modifications.15 Briefly, genomic DNA was bisulfite
converted using the EpiTect Bisulfite Conversion Kit (Qiagen, Hilden,
Germany). PCR amplification was performed with locus-specific primers
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with one primer biotinylated at the 5′ end. For PDLIM2 amplification
reactions, PyroMark PCR Kit (Qiagen) was used. After PCR analyses, single
strands were prepared followed by a denaturation step at 85 °C for 2 min
and final sequencing primer hybridization. Pyrosequencing was performed
using Pyrosequencer ID and DNA methylation analysis software Pyro
Q-CpG 1.0.9 (Biotage, Uppsala, Sweden) that was also used to evaluate the
ratio T:C (mC:C) at CpG sites analyzed. All assays were optimized and
validated using commercially available completely methylated DNA
(Millipore, Darmstadt, Germany) and DNA isolated from peripheral blood
of 10 healthy male and female controls, respectively. The use of human
material was approved by the Ethikkommision of the Charité–Universi-
tätsmedizin Berlin and performed in accordance with the Declaration of
Helsinki. Primers used are listed in Supplementary Table 3.
Statistical analyses of experimental and microarray data
All statistical analyses were done in R v2.9.1 (http://www.r-project.org/) and
GraphPad Prism Version 5.0. One-sided Welch’s t-test was used to analyze
real-time quantitative PCR experiments in Figures 4d and 5a; two-sided
Welch’s t-test was used to analyze data from proliferation experiments,
luciferase assays as well as real-time quantitative PCR experiments. Gene
expression profiles were determined with Illumina HT-12 v 4.0 Expression
BeadChips (Illumina, San Diego, CA, USA). Hybridization was performed in
duplicates from independent transfection experiments. Raw microarray
data were background corrected with Illumina’s proprietary background
correction routine and quantile normalization were applied. Subsequently,
data were log2 transformed. LIMMA was used for determination of
significantly differentially expressed genes. Listed are all genes with a log2
fold change of at least − /+ 0.5 at 72 h (Supplementary Table 6). Microarray
data are available from the Gene Expression Omnibus of the National
Center for Biotechnology Information (GSE86845).
RESULTS
Loss of PDLIM2 expression in HRS cell lines
Given the plethora of activated TFs in cHL and a hypothesized
involvement of the ubiquitin system in this TF activation, we
started our analysis with a literature search on genes associated
with the ubiquitin system, combined with the analysis of
microarray-based gene expression data of HRS and NH cell
lines.17 One of the most interesting candidates was PDLIM2 that is
involved in the control of TF degradation,19,22 and that showed a
loss of expression in several of the HRS compared with NH cell
lines (data not shown). To confirm these data, we analyzed
PDLIM2 mRNA and protein expression levels in an extended panel
of cell lines (Figure 1), including various HRS and NH cell lines
reflecting different B-cell differentiation stages. In contrast to the
robust mRNA expression in the analyzed NH cell lines, PDLIM2
mRNA expression was substantially reduced or lost in seven out of
nine HRS cell lines (L1236, L591, HDLM-2, L540, L540Cy, U-HO1
and SUP-HD1; Figures 1a and b). Interestingly, maintenance of
PDLIM2 expression in L428 and KM-H2 cells correlated with the
presence of deleterious IκB mutations.10,37
At the protein level, we confirmed the loss of PDLIM2
expression in most of the HRS cell lines (Figures 1b and c).
At least three isoforms of PDLIM2 are known with two major
isoforms expressed in the lymphoid compartment.20 These two
isoforms were cloned as controls for PDLIM2 protein expression in
immunoblotting experiments (Supplementary Figure 1). In nearly
all NH B cell lines, robust expression of PDLIM2 was detectable
(Figures 1b and c), whereas among HRS cell lines PDLIM2 protein
expression was only maintained in L428 and KM-H2 cells, for both
of which the correlation with a loss of IκBα protein expression was
confirmed (Figure 1c). If expressed, the cell lines nearly exclusively
expressed PDLIM2 tv 2 (Supplementary Figure 1). Interestingly,
despite PDLIM2 mRNA expression, L1236 cells virtually lacked
PDLIM2 protein expression.
Lack of PDLIM2 expression in HRS cells of primary cHL samples
Next, we determined PDLIM2 protein expression in primary cHL
tissue samples as well as normal lymphoid tissue (Figure 2 and
Supplementary Table 4a). We established immunohistochemical
analyses with two different antibodies that showed consistent
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Figure 1. Loss of PDLIM2 expression in HRS cell lines. (a) PDLIM2
mRNA expression analyses by quantitative (upper panel) and
semiquantitative (lower panel) PCR analyses in various HRS and
NH cell lines, as indicated. (a, upper panel) PDLIM2 mRNA expression
was assessed by real-time quantitative PCR (qPCR) and calculated
using the 2−ΔΔCt method. Expression in Reh cells was set as 1. Error
bars denote 95% confidence intervals. One out of three indepen-
dent experiments is shown. ***Po0.001. (a, lower panel) Analysis of
PDLIM2 and, as a control, GAPDHmRNA expression in the various cell
lines by semiquantitative PCR (sqPCR). One of three independent
experiments is shown. (b) Analysis of PDLIM2 mRNA (upper panel)
and protein (lower panel) expression in HRS (L428, HDLM-2, U-HO1,
SUP-HD1) and NH (BJAB, SU-DHL-4) cell lines, as indicated.
Expression of GAPDH and PARP1 are shown as controls. One of
three independent experiments is shown. WB, western blot analysis.
(c) Analysis of PDLIM2 and IκBα protein expression in various cell
lines, as indicated. Nuclear extracts were analyzed for PDLIM2 (upper
panel), and whole-cell extracts for IκBα (lower panel) protein
expression; expression of PARP1 and β-actin are shown as controls.
One of four independent experiments is shown. Note that L428 and
KM-H2 cells lack IκBα protein expression because of deleterious
NFKBIA mutations or deletions.10
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Figure 2. HRS cells of primary classical HL cases rarely express PDLIM2 and show a recurrent loss of IκBα protein expression. (a, b) Naive
mantle zone B cells present an intense PDLIM2 protein expression, whereas PDLIM2 expression is weak in germinal center B cells (a, × 100;
b, × 200). (c, d) Representative cHL mixed cellularity case with lost PDLIM2 expression (c, × 200, insert, × 400) and lost IκBα expression (d, × 200,
insert, × 400). (e, f) Representative cHL nodular sclerosis case showing lost PDLIM2 expression (e, × 200, insert, × 400). This case shows weak
IκBα protein expression in the HRS cells (f, × 200, insert, × 400). (g, h) In this exceptional cHL mixed cellularity case a membrane-bound PDLIM2
expression pattern occurred (g, × 200, insert, × 400). The IκBα protein expression was typically weak in the HRS cells of this case (h, × 200,
insert, × 400). For all PDLIM2 stainings shown in this figure, a rabbit anti-PDLIM2 antibody was used.
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results. In normal lymphoid tissue, PDLIM2 was expressed in
virtually all lymphoid cells with however reduced expression levels
in germinal center B cells. Furthermore, various B-cell non-
Hodgkin lymphoma cases including 10 follicular lymphoma,
15 diffuse large B-cell lymphoma and 10 Burkitt lymphoma cases
showed PDLIM2 expression in all cases, in the vast majority
of them with a strong staining pattern (Supplementary Figure 2).
In contrast, among 20 cHL cases of various subtypes with or
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Figure 3. DNA methylation of the PDLIM2 promoters in HRS cell lines; altered splicing of PDLIM2 mRNA in L1236 cells. (a, upper panel)
Overview of the regions analyzed (amplicons) for DNA methylation. P1, amplicon of this region corresponds to the region of the transcription
start site (TSS) of the PDLIM2 transcript variant 2 (NM_021630); P2, amplicon of this region corresponds to the region of the TSS of the PDLIM2
transcript variant 1 (NM_176871); pub. reg., a region previously analyzed for methylation.24,25 The percentage GC content of the DNA is shown
in five-base windows. The exon–intron structures of the PDLIM2 transcript variants are diagrammed underneath. (a, lower panel) Result of
bisulfite pyrosequencing in various cell lines, as indicated. The percentage of DNA methylation for each individual CpG element in each
amplicon is represented by a color code (red, CpG site fully methylated (100%); green, CpG site fully unmethylated (0%)). As controls,
commercially available completely methylated DNA (mean methyl. control) and unmethylated pooled DNA extracted from peripheral blood
(mean pool pB) were included. (b) PDLIM2 altered splicing in L1236 cells. (b, left panel) mRNA sequence of a PDLIM2 transcript amplified in
L1236 cells. Shown is the PDLIM2 mRNA sequence with skipping of exon 7 (end of exon 6 is underlined in black, beginning of exon 8 is
underlined in red; according to NM_021630.4) that results in a reading frame shift and generation of a premature STOP (TGA, marked in red).
The wild-type (wt) STOP codon is marked in bold black. (b, right panel) Structure of wt PDLIM2 and the predicted truncated L1236 variant that
results in a C-terminally truncated protein with deletion of the LIM domain (black box, protein sequence out of frame). AA numbers of the
proteins are indicated. (c) PDLIM2 protein variants. HEK293 cells were transfected with empty plasmid (Mock) as a control, or plasmids
encoding PDLIM2 tv2, the L1236 splicing variant (varL1236) or a C-terminally truncated version lacking the LIM domain.22 Western blot (WB)
was performed using antibody ab68220. Expression of PARP1 is shown as control. (d) The PDLIM2 L1236 splicing variant is instable. HEK293
cells were transfected with control plasmid (− ) or plasmids encoding PDLIM2 tv2 or the L1236 splicing variant (PDLIM2 varL1236). At 48 h
after transfection, cells were treated with cycloheximide (CHX). At the indicated times, whole-cell lysates were prepared and analyzed for
expression of the respective PDLIM2 proteins. Expression of PARP1 was analyzed as a control. One of three independent experiments is
shown. Note that the expression level of PDLIM2 varL1236 rapidly decreases following CHX treatment, whereas the expression level of PDLIM2
tv 2 remains stable even after 6 h of CHX treatment.
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without Epstein–Barr virus infection, HRS cells of 19 cases lacked
PDLIM2 expression (Figure 2 and Supplementary Table 4a). In all
cases, PDLIM2 expression was readily detectable in surrounding
cells that served as internal control. Only HRS cells of one case
expressed PDLIM2, and this was however predominantly observed
at the cell membrane (Figure 2g). To investigate a possible
correlation with loss of IκBα expression suggested by the cell line
analyses, we established immunohistochemical analyses of IκBα
using an antibody recognizing the C-terminus of the protein.
cHL cases lacking IκBα expression due to deleterious truncating
mutations would therefore be expected to be negative.10 In 4 of
20 cHL cases (20%), IκBα protein expression was not detectable,
and this is in line with the estimated percentage of deleterious
NFKBIA mutations in cHL in other studies;11 all 4 cases lacked
PDLIM2 expression. We conclude that loss of PDLIM2 expression is
a unifying defect of HRS cells independent of IκB alterations.
Genomic loss of the PDLIM2 gene locus, aberrant PDLIM2
promoter methylation and altered splicing are associated with loss
of PDLIM2 expression in HRS cells
To reveal the underlying molecular mechanisms of loss of PDLIM2
expression in cHL cells, we screened for genomic alterations, DNA
methylation changes and splicing defects. The analysis of
previously published SNP-CHIP data9,38 and subsequent fluores-
cence in situ hybridization analyses (Supplementary Table 2 and
Supplementary Figure 3) indicated deletions of the PDLIM2 locus
in 3 out of 4 cHL cell lines, leading us to analyze primary HRS cells
for chromosomal losses targeting the PDLIM2 gene. For the
primary cases we used FICTION analysis that combined anti-CD30
immunophenotyping with the fluorescence in situ hybridization
probe for 8p21.3—where PDLIM2 is located—and internal
centromere controls. In 5 out of 20 (25%) cases, we observed a
deletion of the PDLIM2 gene in at least 30% of the analyzed HRS
cell nuclei (Supplementary Table 2). Remarkably, in one case with
a deletion targeting the PDLIM2 locus, in some HRS cells the signal
pattern was characteristic for a homozygous deletion. In this case,
an average of 15% of the HRS cell nuclei lacked the fluorescent
probe signal corresponding to the 8p21.3 region harboring
PDLIM2 but showed at least one fluorescent signal for the CEP
probes. Together, these results are well in line with previous array
comparative genomic hybridization studies on primary HRS
cells13,39,40 (for a detailed summary see also Supplementary
Table 5) and suggest that genomic deletions contribute to the
loss of PDLIM2 expression in HRS cells.
An important alternative mechanism of gene silencing in tumor
cells is DNA methylation. We therefore investigated the methyla-
tion status of CpG elements of three different regions in the
vicinity of two major PDLIM2 transcription start sites, including one
previously published region24,25 (Figure 3a and Supplementary
Figure 4). In HRS cell lines without PDLIM2 expression, two DNA
regions (designated as promoter 1 (P1): NM_021630 and promoter 2
(P2): NM_176871) were strongly methylated at the investigated
CpG elements (Figure 3a). The same regions were unmethylated in
DNA from cells with PDLIM2 expression including NH cell lines,
peripheral blood cells from healthy donors or NH mature B cell-
derived lymphomas, as shown for follicular lymphoma (Figures 3a
and 6e and Supplementary Figure 4a). In the previously published
region (located further upstream in the 5′ region of PDLIM2;
designated as pub. reg.) that has been associated with PDLIM2
gene methylation in cancer cells,24 we did not observe alterations
of PDLIM2 DNA methylation in our samples irrespective
of the PDLIM2 expression status (Supplementary Figure 4b).
We conclude that aberrant DNA methylation of the P1 and P2
regions is associated with the loss of PDLIM2 expression in HRS cells.
Furthermore, in L1236 HRS cells we observed a discrepancy
between the—although low—PDLIM2 mRNA but absent protein
expression (see Figure 1). We therefore sequenced the L1236
PDLIM2mRNA to search for sequence alterations (Figure 3b). Apart
from expression of PDLIM2 wt transcripts, we revealed in a fraction
of transcripts skipping of exon 7 (according to NM_021630.4;
skipping of 77 bp), resulting in a frameshift and generation of a
premature termination codon in exon 8 with a predicted protein
size of ∼ 10 kDa smaller than the wt variant and lacking the
C-terminally located LIM domain (Figure 3b), suggesting a loss of
function alteration.22 We cloned this variant (PDLIM2 varL1236)
and confirmed a protein size of ∼ 28 kDa by western blot analysis
(Figure 3c). Remarkably, by treatment of the cells with cyclohex-
imide we revealed a strongly reduced half-life of this truncated
PDLIM2 variant (Figure 3d), indicating reduced protein stability.
Sequencing at the DNA level did not show a genomic alteration in
L1236 cells (data not shown). This splicing variant was not
detected in NH cell lines or Epstein–Barr virus-positive lympho-
blastoid cells (data not shown). Together, our studies indicate that
various mechanisms are associated with the loss of PDLIM2 in HRS
cells, suggesting a selection pressure for PDLIM2 loss in cHL.
Reconstitution of PDLIM2 in HRS cell lines results in reduction of
cell growth, inhibition of NF-κB activity and alteration of
differentially expressed genes
To investigate the biological consequences of the PDLIM2 loss in
HRS cells, we reconstituted PDLIM2 expression in the cell lines
L591, L540Cy and SUP-HD1 (Figure 4a and Supplementary
Figure 5a). In these assays, we observed a significant reduction
of proliferation following PDLIM2 reconstitution, in L591 cells by
∼ 50% and in L540Cy by ∼ 25% (Figure 4b). We did not observe an
alteration of cell viability (data not shown). Given the known role
of PDLIM2 for termination of NF-κB activity22 and of NF-κB for
growth and survival of HRS cells,4,41 we analyzed a possible
inhibition of the NF-κB system following PDLIM2 reconstitution
in HRS cells using NF-κB-dependent reporter gene studies
(Figure 4c and Supplementary Figure 5b). We included the NF-
κB super-repressor IκBαΔN14 as a positive control. As expected, in
these cell lines the constitutive NF-κB activity was strongly
reduced by IκBαΔN. In accordance with an NF-κB inhibitory
function,22 PDLIM2 wt also suppressed the NF-κB activity in HRS
cell lines. In line with a putative loss of function, the truncated
PDLIM2 varL1236 was clearly less effective regarding NF-κB
inhibition, and a previously characterized loss-of-function ΔLIM
variant lacking the LIM domain22 did not alter NF-κB activity
(Supplementary Figure 5b). Together, the loss of PDLIM2
contributes to the enhanced NF-κB activity characteristic for
HRS cells.
To gain insights into PDLIM2-induced transcriptional changes
in HRS cells, we performed genome-wide gene expression
profiling of L591 cells following PDLIM2 reconstitution
by Illumina microarrays. In total, 80 genes showed sig-
nificant expression changes following PDLIM2 reconstitution
(Supplementary Table 6). Genes downregulated by PDLIM2
expression included FBXO32, MAK, IL10RA and IER5 (Figure 4d,
upper panel), and their differential gene expression pattern
between the HL and NH cell lines (Figure 4d, lower panel) was
verified by PCR analyses. These data indicate that the loss
of PDLIM2 in HRS cells contributes to the deregulation of HRS cell-
specific genes.
Superactivation of NF-κB and AP-1 transcriptional activity
following downregulation of PDLIM2 in NH cells
Next, we aimed to investigate the consequences of PDLIM2
downregulation on the transcriptional activity of the NF-κB
and AP-1 TFs in transformed B lymphoid cells (Figure 5).
We transfected Reh and SU-DHL-4 cells with two different
PDLIM2-specific siRNAs (Figure 5a and data not shown). Having
established the PDLIM2 knockdown, we performed NF-κB reporter
assays with these cells. As we hypothesized that the effect of
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PDLIM2 downregulation might be most pronounced following
concomitant stimulation of the respective signaling pathways,
we included stimulation experiments with the phorbol ester PMA
in our reporter gene analyses (Figures 5b and c). As expected,
PMA stimulation alone led to a moderate but significant increase
of NF-κB reporter activity. Importantly, PMA-induced NF-κB
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stimulation in Reh cells was further increased approximately
fivefold following PDLIM2 knockdown (Figure 5b). Similar results
were obtained with SU-DHL-4 cells (Figure 5c). Furthermore,
we investigated the effect of PDLIM2-modulation on AP-1
reporter activity in Reh cells (Figure 5d). As observed for NF-κB,
the PMA-induced AP-1 activity was significantly increased follow-
ing PDLIM2 knockdown. These data indicated that in this
experimental setting PDLIM2 controls inducible TF activities
and that loss of PDLIM2 enhances the activity of NF-κB and
AP-1 TFs.
Downregulation of PDLIM2 in ALCL
ALCL shares several key biological aspects with cHL.42–45
We therefore analyzed PDLIM2 expression in ALCL (Figure 6).
We revealed a striking downregulation or loss of PDLIM2
expression in ALCL cell lines at the mRNA and protein levels
(Figures 6a and b). Similarly, 10 out of 10 ALK-positive and 11 out
of 11 ALK-negative primary ALCL cases lacked PDLIM2 protein
expression as assessed by immunohistochemistry (Figure 6c and
Supplementary Table 4b). We did not observe chromosomal
aberrations of the PDLIM2 gene locus in ALCL (data not shown).
However, the PDLIM2 locus displayed strong methylation at the
P1 and P2 sites in ALCL cell lines lacking PDLIM2 expression
(Figure 6d). Furthermore, we observed hypermethylation mainly
of the P2 site in the majority of primary ALCL cases analyzed
(Figure 6e).
DISCUSSION
Here we describe and functionally characterize the loss of the
putative ubiquitin-E3 ligase PDLIM2 as unifying defect in distinct
lymphoma entities, cHL and ALCL. PDLIM2 has been linked to
tumorigenesis, in particular in colon and breast cancer or HTLV1-
induced adult T-cell leukemia.24,25,46 In these malignancies,
PDLIM2 expression levels are consistently reduced, in part because
of aberrant DNA methylation.24,25 Importantly, reconstitution of
PDLIM2 reduced the tumor growth, suggesting a tumor suppres-
sor function of PDLIM2.24,25,46 However, for most of these
malignancies data on PDLIM2 in primary samples are lacking,
and cancer cell lines used for these studies display significant
PDLIM2 baseline expression levels.24,25 Our data for cHL and
ALCL show the most prominent loss of PDLIM2 expression in
malignancies reported so far, and they support a tumor
suppressor role of PDLIM2: (1) in most HRS and ALCL cells PDLIM2
expression is undetectable, reflecting a functional PDLIM2
deletion; (2) several mechanisms contribute to PDLIM2 silencing,
including aberrant methylation, genomic deletion and altered
splicing, all arguing for selective pressure on this gene locus;
(3) the biological effects observed in HRS cell lines argue for the
functional relevance of lost PDLIM2 expression.
In more detail, in line with the work of Tanaka et al.,22
we demonstrate that PDLIM2 is ubiquitously expressed in
lymphoid cells, with however clearly reduced expression levels
in germinal center B cells, as demonstrated in our work. In
agreement with the expression in lymphoid cells, the analyzed
PDLIM2 promoter regions were unmethylated in peripheral
mononuclear cells from healthy donors. In contrast, PDLIM2
expression was lost and both analyzed PDLIM2 promoter regions
were strongly methylated in HRS cell lines. Thereby, the already
low PDLIM2 expression in germinal center B cells, the putative
cells of origin of cHL,1 might facilitate PDLIM2 silencing in HRS
cells. Of note, we did not observe an altered methylation in a
region previously proposed to be involved in PDLIM2 silencing in
cancer cells,24,25 and this might be because of different epigenetic
regulations of PDLIM2 between cancer and lymphoid cells, or
methodical differences. Importantly, the PDLIM2 gene locus is
located in a minimal deleted region of 600 kb in 8p21.3 in B-cell
non-Hodgkin lymphoma, and TRAIL-R1 and -R2 (tumor necrosis
factor-related apoptosis-inducing ligand receptors 1 and 2) have
been suggested as candidate genes of this deletion.26,27 Our data
suggest that PDLIM2 might be a further candidate gene targeted
by this deletion. Finally, we detected in one HRS cell line a non-
DNA-templated altered splicing pattern leading to an instable,
C-terminally truncated protein lacking the LIM domain. Even
though the relevance of this finding for primary cHL remains
unclear, similarly truncated mutant constructs—generated for
biological studies—lose their putative tumor suppressor function
and the ability to ubiquitinate NF-κB-p65.20,22,24 Together, our
data add the loss of PDLIM2 to the list of defects that target
inducible signaling pathways in cHL.1
We propose that the major implication of the loss of PDLIM2
expression in HRS cells is the generation of a hyperresponsive
cellular background by promoting the sustained activation of TF
activities due to disturbed degradation. This fits with the
observation that HRS cells share hallmark gene expression
patterns with highly activated lymphoid cells and that they are
characterized by the abundant and constitutive activity of
TFs such as NF-κB, AP-1 and STAT that are usually transiently
activated and rapidly downregulated following their induction in
the physiological context.1,5,7 Characteristic for HRS cells is
thereby, apart from the strength of the activation, the plethora
of concomitantly activated TF activities. Because of the involve-
ment of PDLIM2 in the termination of TFs including NF-κB,22
STAT factors19,21 and, as suggested by our work, AP-1, the loss of
PDLIM2 expression in HRS cells provides a molecular mechanism
that contributes to this phenomenon. Our data in Reh cells as well
as previously published data19,22 indicate that knockdown of
Figure 4. PDLIM2 reconstitution in HRS cell lines reduces proliferation and suppresses NF-κB transcriptional activity; analysis of PDLIM2
regulated, differentially expressed genes. (a) The HRS cell lines L591 and L540Cy were transiently transfected with empty plasmid as a control
(Mock) or PDLIM2 (tv 2) expression plasmid (PDLIM2) along with a pEGFP expression plasmid. At 48 h after transfection, transfected GFP+ cells
were enriched and protein expression of PDLIM2 and, as a control, β-actin, was analyzed by western blot (WB). Reh cells with and Mac-2A cells
without PDLIM2 expression (see also Figure 6) as well as empty plasmid (Mock) or PDLIM2-transfected HEK293 cells were included as controls.
(b) PDLIM2 reconstitution reduces proliferation of HRS cell lines. Cells were transfected and enriched as described in (a). At 24, 48 and 72 h
after enrichment, cells were pulsed with 1 μCi [3H]-thymidine per well for a further 20 h, and [3H]-thymidine incorporation was determined.
c.p.m., counts per min. (c) PDLIM2 reconstitution suppresses NF-κB transcriptional activity in HRS cell lines. (c, upper panel) pGL3-basic or
6xκBLuc-constructs were transfected into HRS cell lines together with empty plasmid (Mock; filled bars) or PDLIM2 (gray bars) or IκBαΔN (open
bars) expression constructs. Luciferase activity is shown as fold activation compared with pGL3-basic (set 1). Data are represented as mean
± s.d. (c, lower panel) Expression of PDLIM2, IκBαΔN and, as a control, β-actin in transfected cells was analyzed by WB. Note that IκBαΔN is
significantly smaller than full-length IκBα. One out of five independent experiments is shown. *Po0.05; **Po0.01; ***Po0.001. (d) Analysis of
PDLIM2-regulated genes in L591 HRS cells. L591 cells were transfected and enriched as described in (a). (d, upper panel) FBXO32, IL10RA, MAK
and IER5 mRNA expression was assessed by real-time PCR and calculated using the 2−ΔΔCt method. Expression in Mock-transfected cells was
set as 1. Error bars denote 95% confidence intervals. One out of three independent experiments in shown. **Po0.01; ***Po0.001. (d, lower
panel) Analysis of FBXO32, IL10RA, MAK, IER5 and, as a control, GAPDH mRNA expression in the various cell lines by reverse transcriptase-PCR
(RT-PCR). One of three independent experiments is shown.
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PDLIM2 per se is not sufficient for induction of TF activities, that is,
the respective signaling pathways need to be stimulated for
example by ligand–receptor interactions or constitutive activation
of upstream signaling components. Up to now, several genomic
and molecular defects of such upstream signaling pathway
components involved in NF-κB, Janus kinase (JAK)/STAT and
AP-1 activation are known in HRS cells.1 Whereas most of these
defects target receptor-associated regulatory proteins and rather
proximal located kinase modules, the loss of PDLIM2 in HRS cells
adds a defect at the far end of the respective TF activation
cascades by disabling their nuclear brakes.
Functionally, following PDLIM2 reconstitution in HRS cells the
biological consequences were weaker than previously demon-
strated for, for example, stringent NF-κB inhibition.41 This is
most likely explained by the plethora of upstream defects in
the respective signaling cascades in HRS cells1 and the fact
that PDLIM2 is certainly not the only factor mediating
post-translational modifications of these TFs.47 Furthermore,
experimentally, interfering with TF activities at the far end of
their activation cascade is much more sluggish in comparison
with direct intervention with super-repressors like IκBαΔN.
However, HRS cells will provide an ideal tool to further
investigate the function and mechanisms of action of PDLIM2
in future studies. This is already demonstrated by the
identification of PDLIM2 target genes in our study, the function
of which in cHL has to be investigated in future studies.
In addition, future work will be required to elucidate the exact
mechanism of how PDLIM2 interferes with TF activation in HRS
cells, as ubiquitin-dependent and -independent mechanisms
have been described.19
Remarkably, we identified ALCL as a second lymphoid
malignancy with a consistent loss of PDLIM2 expression.
Importantly, ALCL shares biological similarities with cHL, including
the loss of cellular identity,1,43 a highly activated phenotype (as
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unstimulated cells (set 1). Data are represented as mean± s.d. One of four independent experiments is shown. ***Po0.001.
Loss of PDLIM2 in human lymphoma
KD Wurster et al
610
Leukemia (2017) 602 – 613
exemplified by high-level CD30 expression)42,44 and activation of
AP-1, STAT and NF-κB TFs.5,44,48 Suppression of PDLIM2 occurs
independent of the presence or absence of ALK translocations.
Even though ALK activation contributes to the induction of several
of the TF activities mentioned above,49 the loss of PDLIM2
expression most likely enhances TF activation in ALCL in a similar
manner as described in our work in cHL, and this has to be
investigated in future studies.
Taken together, we have identified the loss of PDLIM2 as a
unifying defect of cHL and ALCL that contributes to the
permanent activation of a plethora of key TFs, thereby
promoting cellular growth and differential gene regulation.
These data increase the complexity of molecular and genomic
defects already known in these lymphoid malignancies. Finally,
such defects of the ubiquitin system might offer an explanation
for the rather disappointing clinical activity of proteasome
inhibitors in cHL.50,51
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